Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178906 | 0.84 | HCAR2 (0.36) | MAOBAPPMMP1MMP9HCAR2 | |
| SCHEMBL21178924 | 0.78 | P2RY12 (0.47) | CSF1RNTRK1NTRK2RAB9AKIT | |
| SCHEMBL21179152 | 0.77 | CYP1A2 (0.46) | CSF1RNTRK1NTRK3NTRK2MAOB | |
| SCHEMBL21177865 | 0.74 | IP6K1 (0.44) | CSF1RNTRK1NTRK3NTRK2MAOB | |
| SCHEMBL21178784 | 0.73 | MAOB (0.45) | CSF1RNTRK1NTRK3NTRK2MAOB | |
| SCHEMBL21187309 | 0.73 | KIT (0.44) | CSF1RNTRK1NTRK3NTRK2MAOB | |
| SCHEMBL27201498 | 0.73 | NPC1 (0.47) | CSF1RNTRK1NTRK3NTRK2MAOB | |
| SCHEMBL21177909 | 0.71 | PDE2A (0.43) | CSF1RNTRK1NTRK3NTRK2MAOB | |
| SCHEMBL30823299 | 0.71 | PDE2A (0.43) | CSF1RNTRK1NTRK3NTRK2MAOB | |
| SCHEMBL17440928 | 0.70 | MAOB (0.45) | CSF1RNTRK1NTRK3NTRK2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269804-B2 | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-08 | — | — | US | disclosed |
| CN-111770921-B | Quinoxalinone compounds, compositions, methods and kits for improving genome editing efficiency | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3740483-B1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMA (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3740483-B1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMA (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3740483-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200361877-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-19 | — | — | US | disclosed |
| CN-111770921-A | Quinoxalinone compounds, compositions, methods and kits for improving efficiency of genome editing | 沃泰克斯药物股份有限公司 | 2020-10-13 | — | — | CN | disclosed |
| WO-2019143677-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143677-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361877-A1 | QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS, AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | XRCC6, LIG1, DCK | CSF1R 4304/4885NTRK1 2676/4885NTRK3 3414/4885 |
| US-12269804-B2 | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency | XRCC6, LIG1, DCK | CSF1R 4304/4885NTRK1 2676/4885NTRK3 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.